NCT01571297 - Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

September 30, 2013

Conditions

Diabetes MellitusDiabetes Mellitus ComplicationsGastroparesis

Interventions

DRUG

RM-131

Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.

DRUG

Placebo

Placebo given subcutaneously for 35 days

Trial Locations (30)

Unknown

Dothan

Tucson

North Little Rock

Concord

Lomita

Los Angeles

Torrance

Hialeah

Inverness

Miami

West Palm Beach

Wichita

Monroe

Chevy Chase

Boston

Farmington Hills

Jackson

Lebanon

Albuquerque

Morehead City

Raleigh

Wilmington

Winston-Salem

Portland

Chattanooga

Germantown

Dallas

Lubbock

Burke

Norfolk